| Literature DB >> 26256392 |
Alexander G Nickel1, Albrecht von Hardenberg1, Mathias Hohl1, Joachim R Löffler1, Michael Kohlhaas1, Janne Becker1, Jan-Christian Reil1, Andrey Kazakov1, Julia Bonnekoh1, Moritz Stadelmaier1, Sarah-Lena Puhl1, Michael Wagner1, Ivan Bogeski2, Sonia Cortassa3, Reinhard Kappl2, Bastian Pasieka2, Michael Lafontaine4, C Roy D Lancaster4, Thomas S Blacker5, Andrew R Hall6, Michael R Duchen7, Lars Kästner8, Peter Lipp8, Tanja Zeller9, Christian Müller9, Andreas Knopp1, Ulrich Laufs1, Michael Böhm1, Markus Hoth2, Christoph Maack10.
Abstract
Mitochondrial reactive oxygen species (ROS) play a central role in most aging-related diseases. ROS are produced at the respiratory chain that demands NADH for electron transport and are eliminated by enzymes that require NADPH. The nicotinamide nucleotide transhydrogenase (Nnt) is considered a key antioxidative enzyme based on its ability to regenerate NADPH from NADH. Here, we show that pathological metabolic demand reverses the direction of the Nnt, consuming NADPH to support NADH and ATP production, but at the cost of NADPH-linked antioxidative capacity. In heart, reverse-mode Nnt is the dominant source for ROS during pressure overload. Due to a mutation of the Nnt gene, the inbred mouse strain C57BL/6J is protected from oxidative stress, heart failure, and death, making its use in cardiovascular research problematic. Targeting Nnt-mediated ROS with the tetrapeptide SS-31 rescued mortality in pressure overload-induced heart failure and could therefore have therapeutic potential in patients with this syndrome.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26256392 DOI: 10.1016/j.cmet.2015.07.008
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287